Comparative Pharmacology
Head-to-head clinical analysis: FOAMICON versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOAMICON versus HC 1.
FOAMICON vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Unknown
Adults: 200 mg orally once daily, with or without food.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
2–4 hours (terminal); prolonged in renal impairment.
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid